Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use
Technology for labeling beta-amyloid plaques, which may be useful in detecting and treating Alzheimer’s disease, has been licensed from the University of California, Los Angeles by P.E.T.Net pharmaceuticals. The Knoxville, TN, company plans to use the technology to develop its own diagnostic tests, as well as to participate in research partnerships with pharmaceutical companies. The tests being developed will utilize positron-emitting molecular probes specific to the plaques and neural tangles associated with Alzheimer’s disease.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.